KRAS vaccine study for people with KRAS-mutated cancers
Treatments studied
Part of Cancer clinical trials.
This trial tests a vaccine designed to target cancers with KRAS mutations. It may be an option if your cancer has a KRAS mutation and you have either tried other treatments without success or have a newly diagnosed, early-stage lung adenocarcinoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer has a KRAS mutation confirmed by genetic testing.
- You have at least one tumor that can be measured on scans.
- You are in generally good health (able to do light activities, score 0–1 on a standard physical function scale).
- Your bone marrow and organs (like liver and kidneys) are working well enough.
- You can understand the study and give written permission to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial is testing a new mRNA vaccine (ABO2102) designed to target KRAS mutations in advanced solid tumors. It may be an option if your cancer has a KRAS mutation and standard treatments are no longer working.
This trial tests a vaccine that targets a specific genetic change (KRAS mutation) in advanced solid tumors like pancreatic and lung cancer. The vaccine is designed to help your immune system fight cancer cells with this mutation.
This trial tests a new vaccine that targets KRAS mutations in patients with colorectal or pancreatic cancer after surgery and chemotherapy. The goal is to see if the vaccine can help prevent the cancer from coming back.
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
This Phase 1 study tests a KRAS-targeted vaccine combined with chemo and immunotherapy (nivolumab and ipilimumab) for people with advanced non-small cell lung cancer. It aims to help the immune system recognize and fight tumors with specific KRAS mutations, and to see if the treatment is safe and effective enough to study further.
This study tests an experimental drug (RX001) given directly into tumors for people with advanced lung cancer that has a KRAS mutation. It is a phase 1 trial, so the main goal is to check safety and find a good dose.
Hear when a new Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.